MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Rajesh V Lalla, Joanne Bowen, Andrei Barasch, Linda Elting, Joel Epstein, Dorothy M Keefe, Deborah B McGuire, Cesar Migliorati, Ourania Nicolatou-Galitis, Douglas E Peterson, Judith E Raber-Durlacher, Stephen T Sonis, Sharon Elad, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO), Noor Al-Dasooqi, Michael Brennan, Rachel Gibson, Janet Fulton, Ian Hewson, Siri B Jensen, Richard Logan, Kerstin E O Öhrn, Triantafyllia Sarri, Deborah Saunders, Inger von Bültzingslöwen, Noam Yarom, Rajesh V Lalla, Joanne Bowen, Andrei Barasch, Linda Elting, Joel Epstein, Dorothy M Keefe, Deborah B McGuire, Cesar Migliorati, Ourania Nicolatou-Galitis, Douglas E Peterson, Judith E Raber-Durlacher, Stephen T Sonis, Sharon Elad, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO), Noor Al-Dasooqi, Michael Brennan, Rachel Gibson, Janet Fulton, Ian Hewson, Siri B Jensen, Richard Logan, Kerstin E O Öhrn, Triantafyllia Sarri, Deborah Saunders, Inger von Bültzingslöwen, Noam Yarom

Abstract

Background: Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis.

Methods: A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.

Results: The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines.

Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy.

Keywords: Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO); gastrointestinal; guidelines; mucositis; oral; stomatitis.

© 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

References

    1. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment‐associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14:505‐515
    1. Vera‐Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem‐cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007;15:491‐496
    1. Vera‐Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106:329‐336
    1. McGuire DB, Altomonte V, Peterson DE, Wingard JR, Jones RJ, Grochow LB. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum. 1993;20:1493‐1502
    1. Duncan GG, Epstein JB, Tu D, et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005;27:421‐428
    1. Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol. 2007;19:323‐327
    1. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy‐induced mucositis. Cancer. 2003;98:1531‐1539
    1. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253‐262
    1. Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation‐induced oral mucositis among patients with head‐and‐neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68:1110‐1120
    1. Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010;16:597‐600
    1. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277‐284
    1. Al‐Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013;21:2075‐2083
    1. Rubenstein EB, Peterson DE, Schubert M, et al;Mucositis Study Section of the Multinational Association for Supportive Care in Cancer ;International Society for Oral Oncology . Clinical practice guidelines for the prevention and treatment of cancer therapy‐induced oral and gastrointestinal mucositis. Cancer. 2004;100(suppl 9):2026‐2046
    1. Sonis ST, Elting LS, Keefe D, et al;Mucositis Study Section of the Multinational Association for Supportive Care in Cancer ;International Society for Oral Oncology . Perspectives on cancer therapy‐induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(suppl 9):1995‐2025
    1. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820‐831
    1. Peterson DE, Bensadoun RJ, Roila F;ESMO Guidelines Working Group . Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(suppl 5):v261‐v265
    1. Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. Prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008;6(suppl 1):S1‐S21; quiz S22–S24.
    1. Bowen JM, Elad S, Hutchins RD, Lalla RV;Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology . Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update. Support Care Cancer. 2013;21:303‐308
    1. Elad S, Bowen J, Zadik Y, Lalla RV;Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology . Development of the MASCC/ISOO Clinical Practice Guidelines for Mucositis: considerations underlying the process. Support Care Cancer. 2013;21:309‐312
    1. Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol. 1996;49:749‐754
    1. Somerfield MR, Padberg JR, Pfister DG, et al. ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Class Pap Curr Comments. 2000;4:881‐886
    1. Gibson RJ, Keefe DM, Lalla RV, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer. 2013;21:313‐326
    1. Raber‐Durlacher JE, von Bultzingslowen I, Logan RM, et al. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:343‐355
    1. Nicolatou‐Galitis O, Sarri T, Bowen J, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:357‐364
    1. Nicolatou‐Galitis O, Sarri T, Bowen J, et al. Systematic review of anti‐inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3179‐3189
    1. Saunders DP, Epstein JB, Elad S, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3191‐3207
    1. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:333‐341
    1. Peterson DE, Ohrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013;21:327‐332
    1. Yarom N, Ariyawardana A, Hovan A, et al. Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3209‐3221
    1. Jensen SB, Jarvis V, Zadik Y, et al. Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3223‐3232
    1. McGuire DB, Fulton JS, Park J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21:3165‐3177
    1. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590‐2598
    1. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy–results of a multicentric randomized German trial in advanced head‐and‐neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161‐1171
    1. Schubert MM, Eduardo FP, Guthrie KA, et al. A phase III randomized double‐blind placebo‐controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer. 2007;15:1145‐1154
    1. Bensadoun RJ, Franquin JC, Ciais G, et al. Low‐energy He/Ne laser in the prevention of radiation‐induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer. 1999;7:244‐252
    1. Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head‐and‐neck cancers: a double‐blind, randomized study. Int J Radiat Oncol Biol Phys. 2006;65:745‐750
    1. Lin YS, Lin LC, Lin SW, Chang CP. Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy‐induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double‐blind, randomized study. Nutr Cancer. 2010;62:682‐691
    1. Meyer F, Bairati I, Fortin A, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long‐term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer. 2008;122:1679‐1683
    1. Lopes NN, Plapler H, Chavantes MC, et al. Cyclooxygenase‐2 and vascular endothelial growth factor expression in 5‐fluorouracil‐induced oral mucositis in hamsters: evaluation of two low‐intensity laser protocols. Support Care Cancer. 2009;17:1409‐1415
    1. Lopes NN, Plapler H, Lalla RV, et al. Effects of low‐level laser therapy on collagen expression and neutrophil infiltrate in 5‐fluorouracil‐induced oral mucositis in hamsters. Lasers Surg Med. 2010;42:546‐552

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi